HOXB7 and Linked Tissue and Blood Biomarkers in the Lungs of Patients With Pulmonary Fibrosis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Biopsy.
- Who it may be relevant to
- Registry conditions: Fibrosis, Pulmonary. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This pilot, multicenter, interventional study investigates the expression of HOXB7 and its associated molecular pathway in lung tissue and blood-derived exosomes from patients with pulmonary fibrosis (PF), including idiopathic pulmonary fibrosis (IPF). Using RNA sequencing (RNA-Seq) and proteomic analysis via mass spectrometry (MS), the study aims to identify tissue and circulating biomarkers associated with fibrosis progression. The study compares different biopsy techniques (surgical vs. transbronchial cryobiopsy) and also includes a control group of patients undergoing lung resection for non-fibrotic conditions.
Interventions
- Procedure Biopsy
This is a non-therapeutic, observational sampling study. Procedures include: Lung tissue sampling via: Surgical biopsy Transbronchial cryobiopsy Explanted lungs from transplant patients Blood sampling for exosome analysis
Primary outcome measures
- HOXB7 Expression [Time frame: Baseline]
Secondary outcome measures (2)
- Assessment of RNA content [Time frame: Baseline]
- Assessment of proteins content [Time frame: Baseline]
Eligibility criteria
Inclusion criteria
- Adults aged 18 to 80 with clinical suspicion of pulmonary fibrosis
- Availability of fresh lung tissue from biopsy or lung explant
- Signed informed consent for research use of biological material and data
Exclusion criteria
\- Refusal to sign informed consent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-control
Study locations
Italy · 1 center
- Azienda Ospedaliero Universitaria Policlinico di Modena — Modena
Identifiers
NCT: NCT07373288 · UModenaReggio20